Literature DB >> 12142050

The development and utilisation of the European Organisation for research and treatment of cancer quality of life group item bank.

A Bottomley1, S Vachalec, K Bjordal, J Blazeby, H Flechtner, P Ruyskart.   

Abstract

One of the problems in assessing patients' quality of life (QL) is the availability of good robust measures that have demonstrated validity, reliability and sensitivity for changes over time, but also have been validated across a large group of culturally diverse nations. The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group (QLG) has recognised this and has established a substantial research programme with the aim of developing such tools, with particular relevance to cancer clinical trials. However, the management of a large set of items in multiple languages is difficult and very labour-intensive. Thus, to support the EORTC QLG research agenda, a computerised web-based database of all EORTC QLG measures and individual questionnaire items was developed. This database allows access to a pool of over 500 validated items in some 6000 translated versions. The database speeds up module development, ensures that questionnaires items have similar wording and provides rapid access to multiple translations.

Entities:  

Mesh:

Year:  2002        PMID: 12142050     DOI: 10.1016/s0959-8049(02)00125-9

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice.

Authors:  Guillaume Mouillet; Antoine Falcoz; Joëlle Fritzsch; Hamadi Almotlak; Pascale Jacoulet; Xavier Pivot; Cristian Villanueva; Laura Mansi; Stefano Kim; Elsa Curtit; Nathalie Meneveau; Olivier Adotevi; Marine Jary; Guillaume Eberst; Angelique Vienot; Fabien Calcagno; Astrid Pozet; Oumelkheir Djoumakh; Christophe Borg; Virginie Westeel; Amélie Anota; Sophie Paget-Bailly
Journal:  Qual Life Res       Date:  2021-01-02       Impact factor: 4.147

2.  A mixed methods approach to adapting health-related quality of life measures for use in routine oncology clinical practice.

Authors:  Clare Harley; Elena Takeuchi; Sally Taylor; Ada Keding; Kate Absolom; Julia Brown; Galina Velikova
Journal:  Qual Life Res       Date:  2011-08-06       Impact factor: 4.147

3.  A decision support system for quality of life in head and neck oncology patients.

Authors:  Joaquim J Gonçalves; Alvaro M Rocha
Journal:  Head Neck Oncol       Date:  2012-02-16

4.  Pragmatic measurement of health satisfaction in people with type 2 diabetes mellitus using the Current Health Satisfaction Questionnaire.

Authors:  Shana B Traina; Hilary H Colwell; Ross D Crosby; Susan D Mathias
Journal:  Patient Relat Outcome Meas       Date:  2015-03-26

5.  The Diabetes Intention, Attitude, and Behavior Questionnaire: evaluation of a brief questionnaire to measure physical activity, dietary control, maintenance of a healthy weight, and psychological antecedents.

Authors:  Shana B Traina; Susan D Mathias; Hilary H Colwell; Ross D Crosby; Charles Abraham
Journal:  Patient Prefer Adherence       Date:  2016-02-29       Impact factor: 2.711

6.  A disease-specific Quality of Life questionnaire for primary aldosteronism.

Authors:  Marieke Stientje Velema; Aline de Nooijer; Ad R M M Hermus; Henri J L M Timmers; Jacques W M Lenders; Olga Husson; Jaap Deinum
Journal:  Endocr Connect       Date:  2019-04       Impact factor: 3.335

7.  Health-Related Quality of Life in Adrenocortical Carcinoma: Development of the Disease-Specific Questionnaire ACC-QOL and Results from the PROFILES Registry.

Authors:  Rebecca V Steenaard; Thomas M A Kerkhofs; Myrte Zijlstra; Floortje Mols; Michiel N Kerstens; Henry J L M Timmers; Rachel S van Leeuwaarde; Koen M A Dreijerink; Elisabeth M W Eekhoff; Els J M Nieveen van Dijkum; Eleonora P M Corssmit; Ellen Kapiteijn; Marjolein N T Kremers; Richard A Feelders; Harm R Haak
Journal:  Cancers (Basel)       Date:  2022-03-08       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.